Allopurinol and global left myocardial function in heart failure patients.
OBJECTIVE
Increased xanthine oxidase (XO) activity may contribute to heart failure pathophysiology. This study evaluated whether a XO inhibitor, allopurinol produces clinical and functional benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy as estimated by global left myocardial function.


METHODS
Fifty-nine patients with a diagnosis of chronic heart failure due to coronary heart disease or idiopathic dilated cardiomyopathy and 20 healthy controls who attended the outpatient clinic of cardiology were subjected to full echocardiographic study including left ventricular diastolic and systolic function, and the combined index of myocardial performance [Tei index: isovolumetric relaxation time (IRT) + isovolumetric contraction time (ICT)/ejection time (ET)]. Patients were randomized to allopurinol (300 mg/day) or placebo. Improvement at 36 weeks was assessed using a composite end point comprising global left cardiac function as well as heart failure morbidity and mortality.


RESULTS
The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving allopurinol or placebo. Allopurinol reduced serum uric acid (SUA) by 1.5 mg/dL (P = 0.001). In a subgroup analysis, patients with elevated SUA (more than 7mg/ dL) responded favorably to allopurinol whereas those with SUA less than 7mg/dL exhibited a trend toward no change. In addition, SUA reduction to allopurinol correlated with favorable clinical and functional response. Within the entire allopurinol patient cohort, those characterized as either improved or unchanged had significantly greater reductions in SUA compared with patients who did not change (P = 0.0007). In placebo patients, lower baseline SUA, but not change in SUA, correlated with improved clinical outcome.


CONCLUSIONS
Allopurinol did not produce significant clinical and functional improvement in unselected patients with moderate-to-severe heart failure. However, it is suggested that it is useful in patients with elevated SUA in a manner according to degree of SUA reduction. SUA may serve as a valuable biomarker to target heart failure therapy.
Department of Cardiology, Suez Canal University, Ismailia, Egypt.
Gamela
G
Nasr
Cherine
C
Maurice
J Cardiol. 1995 Aug;26(2):135-6
7674144
J Am Soc Echocardiogr. 1997 Mar;10(2):169-78
9083973
N Engl J Med. 1999 Sep 2;341(10):709-17
10471456
Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):943-8
17234726
Expert Opin Investig Drugs. 2004 Nov;13(11):1509-16
15500398
Curr Med Res Opin. 2004 Mar;20(3):369-79
15025846
Am J Cardiol. 1998 Nov 1;82(9):1071-6
9817484
Circulation. 1990 Apr;81(4):1161-72
2138525
Hypertension. 2001 Apr;37(4):1069-74
11304505
Circulation. 1977 Apr;55(4):613-8
138494
Lancet. 1999 Jun 12;353(9169):2001-7
10376614
J Am Coll Cardiol. 2008 Jun 17;51(24):2301-9
18549913
Circulation. 2001 Nov 13;104(20):2407-11
11705816
J Physiol. 2004 Mar 16;555(Pt 3):589-606
14694147
Eur Heart J. 1999 Jan;20(2):136-9
10099910
Circ Res. 2007 Mar 30;100(6):894-903
17332431
Circulation. 2002 Jun 4;105(22):2619-24
12045167
Circulation. 1994 Jan;89(1):345-54
8281668
J Cardiol. 1995 Dec;26(6):357-66
8558414
Eur Heart J. 2005 Aug;26(15):1544-50
15872033
Biochem J. 2005 Jun 1;388(Pt 2):501-8
15679468
Am J Cardiol. 1988 Jul 11;62(2):60A-66A
2839019
Circulation. 2004 Oct 12;110(15):2175-9
15466649
Curr Opin Pharmacol. 2002 Apr;2(2):126-30
11950622